ALTEOGEN Inc.

KOSDAQ 196170.KQ

ALTEOGEN Inc. Price to Sales Ratio (P/S) on January 14, 2025: 149.80

ALTEOGEN Inc. Price to Sales Ratio (P/S) is 149.80 on January 14, 2025, a 211.24% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

ALTEOGEN Inc. 52-week high Price to Sales Ratio (P/S) is 227.00 on November 11, 2024, which is 51.53% above the current Price to Sales Ratio (P/S).
ALTEOGEN Inc. 52-week low Price to Sales Ratio (P/S) is 38.23 on February 01, 2024, which is -74.48% below the current Price to Sales Ratio (P/S).
ALTEOGEN Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 131.73.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 196170.KQ

ALTEOGEN Inc.

CEO	Dr. Soon-Jae Park Ph.D.
IPO Date	Dec. 12, 2014
Location	South Korea
Headquarters	62, Yuseong-daero
Employees	145
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

Key trends

Past 5 years